These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 5725924)

  • 21. [Metabolism and tissue distribution of ephedrine 14C in the guinea pig].
    Jacquot C; Rapin JR; Wepierre J; Cohen Y
    Arch Int Pharmacodyn Ther; 1974 Feb; 207(2):298-309. PubMed ID: 4827416
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmacokinetics of absorption, distribution and elimination of fenfluramine and its main metabolite in man.
    Beckett AH; Salmon JA
    J Pharm Pharmacol; 1972 Feb; 24(2):108-14. PubMed ID: 4401963
    [No Abstract]   [Full Text] [Related]  

  • 23. Metabolites of ephedrines in human urine after administration of a single therapeutic dose.
    Tseng YL; Shieh MH; Kuo FH
    Forensic Sci Int; 2006 Mar; 157(2-3):149-55. PubMed ID: 15885945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Studies on the analysis of drugs by use of radioisotopes. VII. Identification of metabolites of ephedrine in rabbit].
    Matsuda A; Baba S; Nagase Y
    Yakugaku Zasshi; 1971 May; 91(5):542-5. PubMed ID: 5105139
    [No Abstract]   [Full Text] [Related]  

  • 25. [Metabolism and tissular distribution of d1-ephedrine 14C].
    Bralet J; Cohen Y; Valette G
    Biochem Pharmacol; 1968 Nov; 17(11):2319-31. PubMed ID: 5718141
    [No Abstract]   [Full Text] [Related]  

  • 26. Drug absorption, metabolism, and excretion. VII. Pharmacokinetics on formation and excretion of the conjugates of N-acetyl-p-aminophenol in rabbits.
    Shibasaki J; Konishi R; Takeda Y; Koizumi T
    Chem Pharm Bull (Tokyo); 1971 Sep; 19(9):1800-8. PubMed ID: 5136477
    [No Abstract]   [Full Text] [Related]  

  • 27. Consequences of the formation of 3,4-dimethyl-5-phenyl-1,3-oxazolidine on the analysis of ephedrines in urine by gas chromatography and a new method for confirmation as N-trifluoroacetyl-O-t-butyldimethylsilyl ether derivatives.
    Sardela VF; Sardela PD; Pereira HM; Aquino Neto FR
    J Chromatogr A; 2011 Mar; 1218(9):1266-72. PubMed ID: 21256502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pseudoephedrine pharmacokinetics in the rat using a microanalysis technique.
    Till AE; Benet LZ
    Pharmacology; 1979; 18(6):306-10. PubMed ID: 493335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biotransformation of D(-)-ephedrine and L(+)-ephedrine in the rabbit, in vivo and in vitro.
    Feller DR; Malspeis L
    Drug Metab Dispos; 1977; 5(1):37-46. PubMed ID: 13974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determination of ephedrines in urine by high-performance liquid chromatography.
    Imaz C; Carreras D; Navajas R; Rodriguez C; Rodriguez AF; Maynar J; Cortes R
    J Chromatogr; 1993 Feb; 631(1-2):201-5. PubMed ID: 8450012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct and rapid quantitation of ephedrines in human urine by paper spray ionization/high resolution mass spectrometry.
    Jeong ES; Kim KH; Cha E; Kwon OS; Cha S; Lee J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1028():237-241. PubMed ID: 27393909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Metabolism, tissue distribution, and mechanism of cardiac fixation of 14C dl pseudoephedrine in rats].
    Jacquot C; Bralet J; Cohen Y
    C R Seances Soc Biol Fil; 1973; 167(12):1789-94. PubMed ID: 4802681
    [No Abstract]   [Full Text] [Related]  

  • 33. Development and validation of an LC-MS/MS method for the quantification of ephedrines in urine.
    Deventer K; Pozo OJ; Van Eenoo P; Delbeke FT
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Feb; 877(4):369-74. PubMed ID: 19144576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Analysis of ephedrine and its metabolites in rat urine by HPLC-ESI-ITMSn].
    Chen Y; Shen SL; Chen HX; Han FM
    Yao Xue Xue Bao; 2005 Sep; 40(9):838-41. PubMed ID: 16342688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detecting doping.
    Erickson BE
    Anal Chem; 2005 Jun; 77(11):211 A. PubMed ID: 15957228
    [No Abstract]   [Full Text] [Related]  

  • 36. Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects.
    Csajka C; Haller CA; Benowitz NL; Verotta D
    Br J Clin Pharmacol; 2005 Mar; 59(3):335-45. PubMed ID: 15752380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal excretion of pseudoephedrine.
    Brater DC; Kaojarern S; Benet LZ; Lin ET; Lockwood T; Morris RC; McSherry EJ; Melmon KL
    Clin Pharmacol Ther; 1980 Nov; 28(5):690-4. PubMed ID: 7438686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of computers in pharmacokinetics.
    Danek A
    Int J Clin Pharmacol Biopharm; 1978 Aug; 16(8):345-50. PubMed ID: 689793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renal excretion of pseudoephedrine in the rat.
    Till AE; Benet LZ
    J Pharmacol Exp Ther; 1979 Dec; 211(3):555-60. PubMed ID: 41938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of beta-methyldigoxin in healthy humans II: Oral studies and bioavailability.
    Hinderling PH; Garrett ER; Wester RC
    J Pharm Sci; 1977 Mar; 66(3):314-25. PubMed ID: 845795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.